Alnylam Pharmaceuticals Inc (ALNY) carries a ŷRobot AI score of 38 out of 100. The model's fair value estimate is $235.12, 7.5% below the last close of $254.07. The chart signal reads Hold.
| Metric | ALNY |
|---|---|
| AI score | 38 / 100 |
| Chart signal | Hold |
| Fair value estimate | $235.12 |
| Upside to fair value | -7.5% |
| Previous close | $254.07 |
| P/E | 41.16 |
| Price / sales | 6.70 |
| Market cap | $34.25B |
| EPS | 5.76 |
| Revenue growth | 38.3% |
| 1-year price change | 11.2% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates Alnylam Pharmaceuticals Inc (ALNY) at $235.12 against a last close of $254.07, implying 7.5% downside to the model's estimate.
The chart-signal model classifies ALNY as Neutral as of Sep 29, 2026, with a signal score of -0.00 on a -1 to 1 scale.
ALNY scores 38 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
ALNY trades at 41.2 times earnings and 6.7 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for ALNY reads -7.3% at 30 days, -5.2% at 90 days, and +11.2% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
Alnylam Pharmaceuticals Inc's revenue growth is +38.3% and free-cash-flow growth is -23.6% on the latest reported figures.
ALNY chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.